Type 2 & other diabetes

Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

Cardiovasc DiabetolPublished Diagnostic accuracy study

Authors' conclusion

Machine learning based modelling using additional ewECG extracted features are superior to NT-proBNP and ARIC HF in SBHF screening among patients with T2DM, providing an alternative HF screening strategy for asymptomatic patients and potentially act as a guidance tool to determine those who required echocardiogram to confirm diagnosis.

Study context

Population
Patients with T2D in two clinical trials of SBHF (DD, reduced GLS [≤18%] or LVH), with 12-lead electrocardiogram (ECG) and echocardiography178 training, 97 validation
Comparison
ewECG machine-learning model vs NT-proBNP and Atherosclerosis Risk in Communities (ARIC) HF risk score for SBHF screening
Outcome
Accuracy (AUC) in identifying SBHF
Methodological detailssupervised machine learning, training and external validation datasets from two clinical trials
  • Supervised machine learning
  • Training and external validation datasets from two clinical trials

Performance

As reported in the abstract

SBHF identification
Test or modelAUC
ewECG0.81 (95% CI 0.787-0.794)
NT-proBNP0.56 (95% CI 0.44-0.68)
ARIC HF0.67 (95%CI 0.56-0.79)

AUC

ewECG0.81 (95% CI 0.787-0.794)
NT-proBNP0.56 (95% CI 0.44-0.68)
ARIC HF0.67 (95%CI 0.56-0.79)
  • ewECG vs NT-proBNP: P < 0.001 — significantly better with ewECG
  • ewECG vs ARIC HF: P = 0.002 — significantly better with ewECG

Further findings

ewECG screening for SBHF components
0.74 (95% CI 0.73-0.74) · AUC for DD · AUC for reduced GLS 0.76 (95% CI 0.73-0.74) · AUC for LVH 0.90 (95% CI 0.88-0.89)

SBHF prevalence

SBHF in training dataset (median 72 years, 41% female)
128 (72%)
SBHF in validation dataset (median 70 years, 43% female)
64 (66%)

Original publication

Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. Published 6 March 2024. doi:10.1186/s12933-024-02141-1

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.